|
JAMA Oncology |
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
Time-Dependent COVID-19 Mortality in Patients With Cancer - An Updated Analysis of the On Covid Registry |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
Time-Dependent COVID-19 Mortality in Patients With Cancer - An Updated Analysis of the OnCovid Registry |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
Time-Dependent COVID-19 Mortality in Patients With CancerAn Updated Analysis of the On Covid Registry |
1 |
Yes |
11/24/2024 |
|
JAMA Oncology |
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates |
1 |
Yes |
12/16/2024 |
|
JAMA Oncology |
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates - A Review |
1 |
Yes |
12/16/2024 |
|
JAMA Oncology |
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer - A US Nationwide Veterans Affairs Study |
1 |
Yes |
12/21/2024 |
|
JAMA Oncology |
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer - A US Nationwide Veterans Affairs Study |
1 |
Yes |
12/21/2024 |
|
JAMA Oncology |
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents |
1 |
Yes |
1/14/2025 |
|
JAMA Oncology |
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents |
1 |
Yes |
1/14/2025 |
|
JAMA Oncology |
Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors |
1 |
Yes |
1/20/2025 |
|
JAMA Oncology |
Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors - A Systematic Review |
1 |
Yes |
1/20/2025 |
|
JAMA Oncology |
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer - A Review |
1 |
Yes |
3/3/2025 |
|
JAMA Oncology |
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer - A Review |
1 |
Yes |
3/3/2025 |
|
JAMA Oncology |
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors |
1 |
Yes |
3/17/2025 |
|
JAMA Oncology |
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors |
1 |
Yes |
3/17/2025 |
|
JAMA Oncology |
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida |
1 |
Yes |
3/18/2025 |
